Entering text into the input field will update the search result below

Akebia jumps 28% after FDA nod for GSK kidney disease therapy

Success business chart with green arrow up and USA dollars background. Profit and money. Financial and business graph. Stock market growth 3d illustration.

JuSun

  • Kidney-disease drug developer Akebia Therapeutics (NASDAQ:AKBA) added ~28% in the morning hours Thursday after GSK (GSK) announced that the FDA approved its anemia treatment Jesduvroq for adults on dialysis due to chronic kidney disease (CKD).
  • An oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor

Recommended For You

About AKBA Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
AKBA--
Akebia Therapeutics, Inc.